Xin Lang Ji Jin·2026-02-26 06:31Group 1 - The core point of the news is that BeiGene's stock price has dropped by 5.27%, currently trading at 264.50 CNY per share, with a total market capitalization of 407.51 billion CNY [1] - BeiGene, established on October 28, 2010, is located in Beijing and specializes in the research, development, production, and commercialization of innovative drugs, with 99.10% of its revenue coming from drug sales and 0.90% from collaboration arrangements [1] Group 2 - From the perspective of major fund holdings, CITIC Prudential Fund has a significant position in BeiGene, holding 11,900 shares in its CITIC Prudential CSI 800 Pharmaceutical Index Fund (LOF) A, which accounts for 1.99% of the fund's net value, ranking it as the tenth largest holding [2] - The CITIC Prudential CSI 800 Pharmaceutical Index Fund (LOF) A was established on January 1, 2021, with a current size of 147 million CNY, and has reported a year-to-date return of 1.77% and a one-year return of 16.18% [2] - The fund manager, Huang Zhi, has been in the position for 7 years and 219 days, overseeing assets totaling 4.418 billion CNY, with the best fund return during his tenure being 146.63% and the worst being -26.08% [2]